Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07744191 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Antiplatelets in Psoriasis

StatusNot Yet Recruiting
PhasePhase 4
Started2026-09
View on ClinicalTrials.gov ↗

Amendment history

2026-08-03
Study Identification, Study Status v1
Study title-11 characters
A Randomized Clinical Trial of Antiplatelets in Psoriasis
2026-07-29
Original filing
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Trial Details
NCT Number NCT07744191
Lead Sponsor NYU Langone Health
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Psoriasis (PsO), Psoriatic Arthritis (PsA)
Enrollment 60 participants
Start Date 2026-09
Primary Completion 2031-09 (estimated)
Study Completion 2031-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-05